Discovery of GHK-Cu in Human Plasma
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide-copper complex that was first isolated from human plasma in 1973 by Loren Pickart. The discovery arose from research comparing the biological activity of plasma from younger and older human donors. Investigators observed that plasma from younger donors promoted certain cellular behaviors in hepatocyte cultures that plasma from older donors did not, and subsequent fractionation work identified GHK-Cu as a contributing factor.
The tripeptide consists of three amino acids — glycine, histidine, and lysine — complexed with a copper(II) ion. The copper binding occurs through the histidine imidazole nitrogen, the glycine amino terminus, and a deprotonated amide nitrogen, forming a square planar coordination geometry. The resulting complex has an approximate molecular weight of 403 daltons.
Since its initial characterization, GHK-Cu has been identified not only in plasma but also in saliva and urine. Published research has documented that circulating levels of GHK-Cu decline with age — a finding that has prompted investigations into the relationship between this peptide complex and age-associated changes in tissue remodeling capacity.
Tripeptide-Copper Complex Structure
The structural chemistry of GHK-Cu has been well characterized in published literature. The tripeptide backbone provides the framework for copper coordination, and the resulting complex has been documented as exhibiting a strong binding affinity for Cu(II) ions. This affinity has been measured at a dissociation constant in the picomolar range, indicating exceptionally tight binding under physiological conditions.
The copper ion within the GHK-Cu complex has been proposed to serve multiple roles. Copper is an essential trace element that participates as a cofactor in numerous enzymatic reactions, including those catalyzed by lysyl oxidase (involved in collagen and elastin cross-linking), superoxide dismutase (involved in antioxidant defense), and cytochrome c oxidase (involved in mitochondrial electron transport). Research has suggested that GHK-Cu may function in part by delivering copper to cells and tissues in a bioavailable form.
The compact size of the GHK-Cu molecule — just three amino acids plus a coordinated metal ion — distinguishes it from larger growth factors and cytokines that also participate in tissue remodeling. This small molecular size has been noted in published literature as potentially relevant to the compound's distribution and cellular uptake properties.
Collagen Synthesis Research
A comprehensive review published in the International Journal of Molecular Sciences by Pickart and Margolina in 2018 documented GHK-Cu's ability to stimulate collagen synthesis in multiple tissue types. The review compiled findings from decades of research, reporting that GHK-Cu promoted the production of type I collagen, the most abundant structural protein in the extracellular matrix of skin, tendon, bone, and other connective tissues.
Research in wound healing models has documented that collagen dressings incorporated with GHK increased collagen synthesis up to nine-fold in rat wound models. This observation has been cited as one of the more prominent quantitative findings in the GHK-Cu literature. Additionally, studies have documented increased production of glycosaminoglycans — large, negatively charged polysaccharides that form a hydrated gel in the extracellular matrix and contribute to tissue hydration and structural integrity.
Research published in Archives of Facial Plastic Surgery by Pollard and colleagues in 2005 demonstrated that GHK-Cu restored replicative vitality to irradiated fibroblasts and increased secretion of growth factors including basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF). These observations were documented in the context of examining approaches to support tissue remodeling in radiation-damaged skin models.
The collagen-related research on GHK-Cu has been summarized alongside full citation details on the GHK-Cu research page.
Gene Expression Modulation
One of the most striking findings in GHK-Cu research emerged from gene profiling studies conducted using the Broad Institute Connectivity Map — a publicly available database that catalogs gene expression changes produced by various small molecules across multiple cell lines. Analysis of GHK-Cu's gene expression signature revealed that the compound can modulate the expression of over four thousand human genes.
Published research has documented that GHK-Cu upregulates genes associated with antioxidant response, including those involved in the production of superoxide dismutase, glutathione S-transferases, and other protective enzymes. Simultaneously, GHK-Cu has been observed to downregulate genes associated with inflammatory signaling, including several interleukins and components of the NF-kB pathway.
This broad gene expression modulation profile has been described in the literature as unusual for a molecule of such small size. The mechanism by which a tripeptide-copper complex influences the expression of thousands of genes remains an active area of investigation. Proposed explanations include copper-mediated activation of transcription factors, modulation of epigenetic regulators, and indirect effects through downstream signaling cascades initiated by copper delivery to intracellular targets.
Wound Healing Research
The wound healing properties of GHK-Cu have been examined across multiple experimental systems. Published studies have documented observations of increased angiogenesis (new blood vessel formation), enhanced nerve outgrowth, and stimulated migration of various cell types including fibroblasts, endothelial cells, and keratinocytes in the presence of GHK-Cu.
Research has documented that GHK-Cu attracted immune cells to wound sites in experimental models, an observation consistent with the compound's proposed role in the inflammatory phase of wound healing. The subsequent transition from inflammation to proliferative repair has also been documented in GHK-Cu-treated models, with investigators noting orderly progression through the recognized phases of wound healing.
The combination of collagen stimulation, angiogenic activity, and immune cell recruitment documented in GHK-Cu research has led investigators to characterize the compound as interacting with multiple phases of the wound healing cascade rather than acting on a single target. This multi-pathway activity profile has been noted as distinguishing GHK-Cu from single-target growth factors in the tissue research literature.
Age-Related Decline of GHK-Cu
Published research has documented that circulating GHK-Cu levels in human plasma decline substantially with age. Levels measured in the plasma of twenty-year-old donors have been reported at approximately 200 nanograms per milliliter, declining to approximately 80 nanograms per milliliter by age sixty. This decline — roughly sixty percent over four decades — has been documented in studies examining the relationship between endogenous peptide levels and age-associated changes in tissue function.
The age-related decline in GHK-Cu has been correlated in published literature with concurrent decreases in collagen production, wound healing efficiency, and antioxidant enzyme expression. While these correlations have been noted in multiple publications, it is important to recognize that correlation does not establish causation, and the specific contribution of declining GHK-Cu levels to age-associated tissue changes remains a subject of ongoing investigation.
GHK-Cu is available as part of the Recovery Stack alongside BPC-157, organized for researchers examining tissue and regeneration pathway signaling. Individual vials are available in the singles catalog.
Research Compliance Disclaimer
All information presented in this article reflects outcomes and observations reported in published research studies. GHK-Cu is sold strictly for in vitro research, laboratory use, and scientific investigation only. It is not intended for human consumption, veterinary use, or any diagnostic or therapeutic application. No information in this article constitutes medical advice or therapeutic guidance.